Chapter 2 Lung cancer staging and TNM classification

  • Slides: 4
Download presentation
Chapter 2 Lung cancer staging and TNM classification

Chapter 2 Lung cancer staging and TNM classification

Lung cancer staging and TNM classification • The most frequently used system to stage

Lung cancer staging and TNM classification • The most frequently used system to stage lung cancer is the American Joint Committee on Cancer TNM system, which is based on: 1 – The size of the main tumour (T) and whether it has grown into nearby areas – Whether the cancer has spread to nearby (regional) lymph nodes (N) – Whether the cancer has metastasised (M) to other organs of the body • Once the T, N and M categories have been defined, this information is combined to assign an overall stage of 0, I, III or IV 1 • This process is called stage grouping 1 • It produces a range of anatomical stage or prognostic groups (right)1 TNM, tumour, node, metastasis. This information is from an international website which is intended for healthcare professionals not located in the United States of America (US) and the United Kingdom (UK). 1. American Joint Committee on Cancer. Lung cancer staging. 7 th ed. 2009. https: //cancerstaging. org/references-tools/quickreferences/Documents/Lung. Medium. pdf (Accessed: 05 October 2018). 2

Lung cancer TNM classification in more detail 1 T Comments TX Primary tumour cannot

Lung cancer TNM classification in more detail 1 T Comments TX Primary tumour cannot be assessed, or tumour proven by the presence of malignant cells in sputum or bronchial washings but not visualised by imaging or bronchoscopy T 0 No evidence of primary tumour Tis Carcinoma in situ T 1 Tumour 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (for example, not in the main bronchus)* T 1 a Tumour 2 cm or less in greatest dimension T 1 b Tumour more than 2 cm but 3 cm or less in greatest dimension T 2 Tumour more than 3 cm but 7 cm or less or tumour with any of the following features (T 2 tumours with these features are classified T 2 a if 5 cm or less): involves main bronchus, 2 cm or more distal to the carina; invades visceral pleura (PL 1 or PL 2); associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung T 2 a Tumour more than 3 cm but 5 cm or less in greatest dimension T 2 b Tumour more than 5 cm but 7 cm or less in greatest dimension T 3 Tumour more than 7 cm or one that directly invades any of the following: parietal pleural (PL 3), chest wall (including superior sulcus tumours), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumour in the main bronchus less than 2 cm distal to the carina* but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumour nodule(s) in the same lobe T 4 Tumour of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, carina, separate tumour nodule(s) in a different ipsilateral lobe *The uncommon superficial spreading tumour of any size with its invasive component limited to the bronchial wall, which may extend proximally to the main bronchus, is also classified as T 1 a. PL, pleural; TNM, tumour, node, metastasis. This information is from an international website which is intended for healthcare professionals not located in the United States of America (US) and the United Kingdom (UK). 1. American Joint Committee on Cancer. Lung cancer staging. 7 th ed. 2009. https: //cancerstaging. org/references-tools/quickreferences/Documents/Lung. Medium. pdf (Accessed: 05 October 2018). 3

Lung cancer TNM classification in more detail (cont’d)1 N Comments NX Regional lymph nodes

Lung cancer TNM classification in more detail (cont’d)1 N Comments NX Regional lymph nodes cannot be assessed N 0 No regional lymph node metastasis N 1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension N 2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) N 3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s) M Comments M 0 No distant metastasis M 1 Distant metastasis M 1 a Separate tumour nodule(s) in a contralateral lobe, tumour with pleural nodules or malignant pleural (or pericardial) effusion* M 1 b Distant metastasis (in extrathoracic organs) *Most pleural (and pericardial) effusions with lung cancer are due to tumours. In a few patients, however, multiple cytopathological examinations of pleural (pericardial) fluid are negative for tumours, and the fluid is non-bloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion is not related to the tumour, the effusion should be excluded as a staging element and the patient should be classified as M 0. TNM, tumour, node, metastasis. This information is from an international website which is intended for healthcare professionals not located in the United States of America (US) and the United Kingdom (UK). 1. American Joint Committee on Cancer. Lung cancer staging. 7 th ed. 2009. https: //cancerstaging. org/references-tools/quickreferences/Documents/Lung. Medium. pdf (Accessed: 05 October 2018). 4